Partner Stories
Our global partnerships are built on shared values, trust, and a commitment to making healthcare accessible and affordable for people across the world. Hear it from our partners how we have worked together to transform the global healthcare landscape, strengthen communities, and shape a healthier future for all. Collaboration meets compassion in each testimonial, as we join hands to create a lasting impact.
Leonard Ariff Abdul Shatar
Group Managing Director, Duopharma Biotech Berhad
Our Business Partner in Malaysia since 2012
“The strategic partnership between Duopharma Biotech Berhad, Malaysia’s leading pharmaceutical company and Biocon has brought affordable cancer and insulin therapeutic options to the country.
The partnership of Biocon Biologics and Duopharma Biotech has established both these companies as key players in the diabetes and cancer markets, with the government, healthcare professionals and patients.
It is our hope that the continued future collaboration of Biocon Biologics and Duopharma Biotech will bring our companies even closer and ‘provide smarter solutions for a healthier life’ to patients and customers in Malaysia and neighbouring countries.”
“We believe that Libbs has contributed to Biocon Biologic’s development in the three important areas of regulatory, tech transfer and marketing, in Brazil. Our teams have worked together to build knowledge and wealth for both the companies. Together, we have made a significant impact on public health by improving access to biosimilars in Brazil.”
Alcebíades de Mendonça Athayde Jr.
CEO, Libbs Farmacêutica
Biocon’s Business Partner in Brazil since 2011
Oscar Osorio Arechavaleta
Director General, Laboratorios PiSA,
Our Business Partner in Mexico since 2002
“Laboratorios PiSA is proud to have been one of Biocon Biologic’s earliest partners for human insulin. Mexico has one of the highest prevalence rates of diabetes in the world, and because we recognised early on the importance of Biocon Biologic’s insulin, we have been able to significantly increase insulin access for diabetes patients in Mexico. Today, the vast majority of diabetes patients in Mexico receive the insulin produced through our partnership.
Our partnership is built on a shared commitment to provide affordable access to insulins to patients, and we look forward to delivering on that promise together in the years ahead.”
